Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2016 Mar;9(Spec Feature):106-10.

V体育官网入口 - Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Loretta Fala

Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Loretta Fala. Am Health Drug Benefits. 2016 Mar.
No abstract available

PubMed Disclaimer

References

    1. Asthma & Allergy Center. Asthma statistics. "V体育ios版" www.asthmaandallergycenter.net/education/asthma/asthma-statistics. Accessed February 22, 2016.
    1. Bel EH, Wenzel SE, Thompson PJ, et al; for the SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371: 1189–1197. - "VSports最新版本" PubMed
    1. ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003; 22: 470–477. - PubMed
    1. US Food and Drug Administration. FDA approves Nucala to treat severe asthma. Press release. November 4, 2015. "V体育官网入口" www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm. Accessed December 3, 2015.
    1. Pavord ID, Kom S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380: 651–659. - PubMed

LinkOut - more resources